Rankings
▼
Calendar
EBS Q3 2016 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena
EBS
Emergent BioSolutions Inc.
$430M
Q3 2016 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$143M
Gross Profit
$76M
53.3% margin
Operating Income
$35M
24.8% margin
Net Income
$21M
14.9% margin
EPS (Diluted)
$0.45
QoQ Revenue Growth
+56.6%
Cash Flow
Operating Cash Flow
$27M
Free Cash Flow
$10M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$932M
Total Liabilities
$384M
Stockholders' Equity
$548M
Cash & Equivalents
$299M
← FY 2016
All Quarters
Q4 2016 →
